Kato K - Search Results

1

Immunotherapy for Unresectable Small Bowel Adenocarcinoma: A Case Series.

Sugiyama K, Owaki S, Sato M, Shiraishi K, Kato K, Kitagawa C. Sugiyama K, et al. Among authors: kato k. In Vivo. 2024 Jan-Feb;38(1):518-522. doi: 10.21873/invivo.13469. In Vivo. 2024. PMID: 38148069 Free PMC article.

2

The Impact of Nutritional Support on Survival Outcomes in Patients with Advanced Gastric Adenocarcinoma Treated with Chemotherapy.

Sugiyama K, Shiraishi K, Motohashi T, Onoda S, Sato M, Kato K, Uda H, Hattori M, Suenaga M, Hirashima N, Shimada M, Kataoka M, Kitagawa C. Sugiyama K, et al. Among authors: kato k. Nutr Cancer. 2023;75(3):867-875. doi: 10.1080/01635581.2022.2162090. Epub 2023 Jan 2. Nutr Cancer. 2023. PMID: 36591915

3

Second-line Chemotherapy for Previously Treated Metastatic Small Bowel Adenocarcinoma: A Retrospective Analysis.

Nakazawa T, Narita Y, Kumanishi R, Ogata T, Matsubara Y, Nozawa K, Kato K, Honda K, Masuishi T, Bando H, Kadowaki S, Ando M, Hara K, Tajika M, Muro K. Nakazawa T, et al. Among authors: kato k. Anticancer Res. 2021 Oct;41(10):5147-5155. doi: 10.21873/anticanres.15332. Anticancer Res. 2021. PMID: 34593466

4

Prospective Survey of Financial Toxicity Measured by the Comprehensive Score for Financial Toxicity in Japanese Patients With Cancer.

Honda K, Gyawali B, Ando M, Kumanishi R, Kato K, Sugiyama K, Mitani S, Masuishi T, Narita Y, Bando H, Taniguchi H, Kadowaki S, Ura T, Muro K. Honda K, et al. Among authors: kato k. J Glob Oncol. 2019 May;5:1-8. doi: 10.1200/JGO.19.00003. J Glob Oncol. 2019. PMID: 31070981 Free PMC article.

5

A Phase II Study of Modified FOLFOX6 for Advanced Gastric Cancer Refractory to Standard Therapies.

Mitani S, Kadowaki S, Komori A, Kondoh C, Oze I, Kato K, Masuishi T, Honda K, Narita Y, Taniguchi H, Ando M, Tanaka T, Tajika M, Muro K. Mitani S, et al. Among authors: kato k. Adv Ther. 2020 Jun;37(6):2853-2864. doi: 10.1007/s12325-020-01358-2. Epub 2020 May 7. Adv Ther. 2020. PMID: 32378071 Clinical Trial.

6

Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for patients with metastatic colorectal cancer.

Matsubara Y, Masuishi T, Ogata T, Nakazawa T, Kato K, Nozawa K, Narita Y, Honda K, Bando H, Taniguchi H, Kadowaki S, Ando M, Tajika M, Muro K. Matsubara Y, et al. Among authors: kato k. J Cancer Res Clin Oncol. 2023 Mar;149(3):1123-1129. doi: 10.1007/s00432-022-03979-2. Epub 2022 Mar 22. J Cancer Res Clin Oncol. 2023. PMID: 35314873 Clinical Trial.

7

Efficacy of Cytotoxic Agents After Progression on Anti-PD-(L)1 Antibody for Pre-treated Metastatic Gastric Cancer.

Kato K, Narita Y, Mitani S, Honda K, Masuishi T, Taniguchi H, Kadowaki S, Ura T, Ando M, Tajika M, Muro K. Kato K, et al. Anticancer Res. 2020 Apr;40(4):2247-2255. doi: 10.21873/anticanres.14187. Anticancer Res. 2020. PMID: 32234921

8

Clinical Impact of Oral Intake in Second-line or Third-line Chemotherapy for 589 Patients With Advanced Gastric Cancer: A Retrospective Cohort Study.

Ogata T, Narita Y, Kumanishi R, Nakazawa T, Matsubara Y, Kato K, Nozawa K, Honda K, Masuishi T, Bando H, Kadowaki S, Ando M, Tajika M, Muro K. Ogata T, et al. Among authors: kato k. Am J Clin Oncol. 2021 Aug 1;44(8):388-394. doi: 10.1097/COC.0000000000000835. Am J Clin Oncol. 2021. PMID: 34028372

9

The impact of combined PD-L1 positive score on clinical response to nivolumab in patients with advanced esophageal squamous cell carcinoma.

Matsubara Y, Toriyama K, Kadowaki S, Ogata T, Nakazawa T, Kato K, Nozawa K, Narita Y, Honda K, Masuishi T, Bando H, Ando M, Tajika M, Oze I, Hosoda W, Muro K. Matsubara Y, et al. Among authors: kato k. Esophagus. 2023 Jul;20(3):524-532. doi: 10.1007/s10388-022-00978-7. Epub 2023 Jan 3. Esophagus. 2023. PMID: 36595124

10

The survival benefit of increasing the number of active drugs for metastatic colorectal cancer: A multicenter retrospective study.

Kawakami T, Masuishi T, Kawamoto Y, Go H, Kato K, Kumanishi R, Sawada K, Yuki S, Yamamoto K, Komatsu Y, Muro K, Fushiki K, Shirasu H, Yamazaki K. Kawakami T, et al. Among authors: kato k. Cancer Med. 2022 Jun;11(11):2184-2192. doi: 10.1002/cam4.4599. Epub 2022 Feb 19. Cancer Med. 2022. PMID: 35182029 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

9,659 results

Search Page